3-[(cyclopropanecarbonylamino)methyl]-N-propan-2-yl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole-5-carboxamide
C14H21N5O2 — CID 118740610
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[(cyclopropanecarbonylamino)methyl]-N-propan-2-yl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole-5-carboxamide
3-[(cyclopropanecarbonylamino)methyl]-N-propan-2-yl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole-5-carboxamide (PubChem CID 118740610) has the molecular formula C14H21N5O2 and a molecular weight of 291.35 g/mol. Its IUPAC name is 3-[(cyclopropanecarbonylamino)methyl]-N-propan-2-yl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole-5-carboxamide.
Molecular Properties
| Compound Name | 3-[(cyclopropanecarbonylamino)methyl]-N-propan-2-yl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole-5-carboxamide |
|---|---|
| PubChem CID | 118740610 |
| Molecular Formula | C14H21N5O2 |
| Molecular Weight | 291.35 g/mol |
| Exact Mass | 291.17 |
| IUPAC Name | 3-[(cyclopropanecarbonylamino)methyl]-N-propan-2-yl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole-5-carboxamide |
| SMILES | CC(C)NC(=O)C1CCc2nnc(CNC(=O)C3CC3)n21 |
| InChI | InChI=1S/C14H21N5O2/c1-8(2)16-14(21)10-5-6-11-17-18-12(19(10)11)7-15-13(20)9-3-4-9/h8-10H,3-7H2,1-2H3,(H,15,20)(H,16,21) |
| InChIKey | SULBLCWVVNAQLZ-UHFFFAOYSA-N |
| XLogP | 0.32 |
| TPSA | 88.91 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 21 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 291.35 |
| LogP ≤ 5 | 0.32 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118740610 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.